Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M55.8Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-1.1
Enterprise Value $M35.1EPS (TTM) $-0.1Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %-3.1Quick Ratio12.7Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %-10.8Current Ratio12.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-49.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-67.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M237ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

RNN is held by these investors:

RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Jeong Tae HeumCFO 2015-01-12Sell317,272$0.91-73.63view
Ahn Chang HoDirector 2015-01-12Sell314,656$0.91-73.63view
Ahn Chang HoDirector 2014-06-12Sell136,193$0.99-75.76view
Jeong Tae HeumCFO 2013-09-09Sell71,139$0.46-47.83view
Kivel RichardDirector 2011-10-03Buy2,500$1.04-76.92view
Brandt Peter C.Director 2011-09-09Buy125,000$1.17-79.49view
Brandt Peter C.Director 2011-09-07Buy25,000$0.96-75view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy1,008,078$1.31-81.68view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy320,846$1.22-80.33view
McIntosh David MDirector 2009-07-30Buy5,600$0.8-70view

Quarterly/Annual Reports about RNN:

News about RNN:

Articles On GuruFocus.com
Weekly CEO Buys Highlight: RNN, IIG, FSC, GEO, DAN May 21 2011 
Weekly CEO Buys Highlight: GBDC, EXL, RNN, KYN, CMTL Apr 09 2011 

More From Other Websites
REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Feb 24 2017
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with... Feb 23 2017
Rexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 06 2017
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in... Jan 20 2017
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017 Jan 03 2017
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017 Jan 03 2017
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Shareholder Director Nominations Nov 25 2016
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 04 2016
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for... Oct 31 2016
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of... Oct 26 2016
Rexahn Pharmaceuticals Nears 52-Week Low (RNN) Oct 11 2016
Rexahn Pharmaceuticals to Present Trial Data (RNN) Oct 06 2016
Key FDA Decisions and Trial Results Expected in October Oct 04 2016
Rexahn Pharmaceuticals (RNN) Sees Hammer Chart Pattern: Time to Buy? Sep 26 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 20 2016
Rexahn Announces $6 Million Registered Direct Offering Sep 14 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 14 2016
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or... Sep 12 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)